News Releases

ELIAS Animal Health Expands Immunotherapy Portfolio with New Partnership, New Clinical Trial

by Emily McVey | Jan 19, 2022

ELIAS Animal Health continues the expansion of its treatment portfolio with the recent announcement of an exciting new partnership with Genelux Corporation, a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.

ELIAS In-Licenses Oncolytic Immunotherapy Treatment for Companion Animals from Genelux Corporation

In November, it was announced that ELIAS Animal Health obtained an exclusive worldwide licensing agreement with Genelux Corporation for V-VET1, its clinical-stage animal health product candidate. V-VET1 is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis). ELIAS Animal Health is planning clinical trials to evaluate and develop V-VET1 as a potential new immunotherapy option for treating cancer in pets. 

Genelux conducted a Phase 1 study in which V-VET1 was administered to canines with several different types of cancer, including mast cell tumors, osteosarcoma, soft tissue sarcoma, anal gland carcinoma and T cell lymphoma. No maximum tolerated dose was reached in this dose-escalation trial and dogs tolerated their infusions well. Evidence of antitumor responses and of disease control were observed. 

“We are thrilled to announce our exclusive license for V-VET1 to help veterinarians treat the many pets who are diagnosed with cancer every year,” said Tammie Wahaus, CEO of ELIAS Animal Health. “Companion animal cancer treatments have made little progress in the past few decades, and this partnership is an exciting step in broadening the cancer treatment options available in veterinary medicine.”

Read more about the agreement here.

About ELIAS Animal Health
ELIAS Animal Health is a medical biotechnology company advancing its novel targeted T cell-based immunotherapies for the treatment of canine cancers. The ELIAS cancer immunotherapy is being distributed to veterinarians commercially under 9 CFR 103.3 as an experimental autologous prescription product for the treatment of canine osteosarcoma. The company’s novel therapeutic approach offers the prospect of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. For more information, visit



Tweet @AHCorridor

Media Coverage

The Connector

KC Animal Health Blog